2025-12-19 - Analysis Report
Okay, here's a comprehensive report on Northrop Grumman (NOC) based on the data provided:

**1) Return Rate Comparison:**

*   **Company Overview:** Northrop Grumman Corp. is an aerospace and defense technology company.
*   **NOC Cumulative Return:** 45.18%
*   **VOO (S&P 500) Cumulative Return:** 99.09%
*   **Divergence:** -52.2 (Relative Divergence: 6.2)
*   **Analysis:** NOC has significantly underperformed the S&P 500 over the period examined. The divergence of -52.2 indicates a substantial difference in cumulative returns, with NOC lagging. The relative divergence of 6.2 suggests that the current divergence is near the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta  | Cap(B) |
|------------|---------|--------|---------|-------|--------|
| 2015-2017  | 46.0%   | 65.6%  | 17.0%   | 0.0   | 43.9   |
| 2016-2018  | -2.0%   | 74.3%  | -17.0%  | 0.0   | 35.1   |
| 2017-2019  | 17.0%   | 79.2%  | -5.0%   | 0.9   | 49.2   |
| 2018-2020  | -28.0%  | 79.9%  | -52.0%  | 0.8   | 43.6   |
| 2019-2021  | 43.0%   | 79.9%  | -4.0%   | 0.8   | 55.4   |
| 2020-2022  | 18.0%   | 79.9%  | 19.0%   | 0.3   | 78.1   |
| 2021-2023  | 24.0%   | 82.7%  | 23.0%   | 0.2   | 67.0   |
| 2022-2024  | -15.0%  | 82.7%  | -36.0%  | 0.2   | 67.2   |
| 2023-2025  | -5.0%   | 82.1%  | -69.0%  | 0.1   | 80.1   |

*   **CAGR:** Fluctuates significantly, showing periods of high growth and decline.
*   **MDD:** Consistently high Maximum Drawdown, indicating significant potential for losses.
*   **Alpha:**  Alpha is highly variable, ranging from -69% to 23%, implying periods of both significant outperformance and underperformance relative to its benchmark. Alpha generally decreased over the period.
*   **Beta:** Beta generally ranges from 0.0 to 0.9, indicating lower volatility than the market. It has generally decreased over the period.
*   **Cap(B):**  Market capitalization has generally increased.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 559.52
*   **Previous Close:** 564.19
*   **Change:** -0.83
*   **5-day SMA:** 567.60
*   **20-day SMA:** 560.71
*   **60-day SMA:** 581.61
*   **Analysis:** The current price is below the 5-day and 60-day SMAs, but close to the 20-day SMA. This suggests a short-term downtrend, as the price has fallen below the short-term moving averages.

**3) RSI, PPO, and Divergence/Return Analysis:**

*   **MRI:** 0.7 (Medium Investment Recommended)
*   **RSI:** 42.45
*   **PPO:** 0.37
*   **Hybrid Signal:**  "cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Dividend_2.31 Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)" - This signal suggests a buy recommendation with no cash allocation, and implies a low cash ratio for the end of the year.
*   **Recent Divergence Change:** 5.2 (+) (단기상승 - Short-term Increase)
*   **Expected Return:** -120.2%

*   **Analysis:** The MRI indicates a "Medium Investment" recommendation. The RSI is below 50, suggesting potential for further price decline or consolidation. The positive recent divergence change indicates a short-term upward trend, but the extremely negative expected return suggests a significant long-term underperformance is anticipated. The Hybrid Signal suggests a buy, possibly contradicting the expected return. The recent price drop suggests a slight fluctuation issue.

**4) Recent News & Significant Events:**

*   **Earnings Release Date:** Northrop Grumman announced the date for its Q4 and full-year 2025 earnings release.
*   **Institutional Selling:** Texas Permanent School Fund Corp sold shares of NOC.
*   **Value Assessment:** Articles discuss reassessing NOC's valuation after a recent pullback and the stock's overall performance.
*   **Sell Recommendation:** One article suggests reasons to sell NOC.
*   **Options Strategy:** An article discusses using options to boost yield from NOC.

**Analysis:** Recent news is mixed. The upcoming earnings release could be a catalyst for price movement. The institutional selling may create downward pressure. Analyst opinions are varied, with some reassessing valuation and others recommending selling.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (2.04 on a 1-5 scale)
*   **Opinions:** 21
*   **Target Price:** Average: 662.68 / High: 770.00 / Low: 533.00
*   **Recent Rating Changes:** No changes reported in the provided data.

*   **Analysis:** The analyst consensus is a "Buy" rating with a significant upside potential based on the average target price. However, the wide range between the high and low target prices suggests uncertainty among analysts.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-10-21 | 7.69  | 10.42 B$    |
| 2025-07-22 | 8.17  | 10.35 B$    |
| 2025-04-22 | 3.33  | 9.47 B$     |
| 2024-10-24 | 7.02  | 10.00 B$    |
| 2025-10-21 | 7.02  | 10.00 B$    |

*   **Analysis:** Revenue has been relatively stable, fluctuating around $10 billion. EPS has been more volatile, with a noticeable dip in Q2 2025.

**6) Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $10.42B    | 21.37%        |
| 2025-06-30   | $10.35B    | 21.35%        |
| 2025-03-31   | $9.47B     | 16.69%        |
| 2024-12-31   | $10.69B    | 18.08%        |
| 2024-09-30   | $10.00B    | 21.07%        |

Capital and Profitability:

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-09-30   | $15.99B    | 6.88%     |
| 2025-06-30   | $15.47B    | 7.59%     |
| 2025-03-31   | $14.98B    | 3.21%     |
| 2024-12-31   | $15.29B    | 8.27%     |
| 2024-09-30   | $14.75B    | 6.96%     |

*   **Analysis:** Revenue is generally stable with small quarterly variations. Profit margins have been strong, mostly above 21% but dipped in Q1 2025. Equity has been increasing steadily. ROE has fluctuated, with a low point in Q1 2025, suggesting variable profitability.

**7) Comprehensive Analysis:**

*   **Underperformance:** NOC has significantly underperformed the S&P 500, with a considerable negative divergence.
*   **Mixed Signals:** While analyst consensus is a "Buy" and the MRI suggests a "Medium Investment," the extremely negative expected return and articles suggesting to "Sell" NOC indicate caution is warranted.
*   **Financial Stability:** Revenue, profit margins, and equity are relatively stable, suggesting a sound financial base for the company.
*   **Volatile EPS:** EPS is more volatile, which may concern investors.
*   **Short-Term Uptick:** Recent divergence change indicates a short-term uptick.
*   **Price Below Moving Averages:** The current price is below the 5-day and 60-day SMAs, indicating a short-term downtrend.

**Conclusion:**

Investing in Northrop Grumman presents a mixed picture. While the company exhibits financial stability and analysts have a positive outlook, it has significantly underperformed the market. The highly negative expected return is a significant concern, which outweighs the buy recommendation. Investors should carefully weigh these factors and consider their risk tolerance before investing in NOC. Further research into the reasons behind the negative expected return is crucial.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.